BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9392397)

  • 1. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations.
    Nowak-Göttl U; Ahlke E; Klösel K; Jürgens H; Boos J
    Eur J Pediatr; 1997 Nov; 156(11):848-50. PubMed ID: 9392397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation.
    Nowak-Göttl U; Ahlke E; Schulze-Westhoff P; Boos J
    Br J Haematol; 1996 Oct; 95(1):123-6. PubMed ID: 8857948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
    Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
    Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
    Nowak-Göttl U; Werber G; Ziemann D; Ahlke E; Boos J
    Haematologica; 1996; 81(2):127-31. PubMed ID: 8641640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
    Ahlke E; Nowak-Göttl U; Schulze-Westhoff P; Werber G; Börste H; Würthwein G; Jürgens H; Boos J
    Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
    Risseeuw-Appel IM; Dekker I; Hop WC; Hählen K
    Med Pediatr Oncol; 1994; 23(4):335-43. PubMed ID: 8058004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
    Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
    Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
    Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia.
    Semeraro N; Montemurro P; Giordano P; Schettini F; Santoro N; De Mattia D; Giordano D; Conese M; Colucci M
    Thromb Haemost; 1990 Aug; 64(1):38-40. PubMed ID: 2274927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol.
    Kirschke R; Nürnberger W; Eckhof-Donovan S; Nürnberger I; Göbel U
    Klin Padiatr; 1998; 210(4):285-90. PubMed ID: 9743967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
    Albertsen BK; Schrøder H; Jakobsen P; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Clin Pharmacol; 2001 Oct; 52(4):433-7. PubMed ID: 11678787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
    Appel IM; Hop WC; Pieters R
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study.
    Rosen O; Müller HJ; Gökbuget N; Langer W; Peter N; Schwartz S; Hähling D; Hartmann F; Ittel TH; Mück R; Rothmann F; Arnold R; Boos J; Hoelzer D
    Br J Haematol; 2003 Dec; 123(5):836-41. PubMed ID: 14632774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in procoagulant, anticoagulant, and fibrinolytic systems before and after start of induction chemotherapy in children with acute lymphoblastic leukemia.
    Albayrak M; Gürsel T; Kaya Z; Koçak U
    Clin Appl Thromb Hemost; 2013; 19(6):644-51. PubMed ID: 22751908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.